We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Metabolon, Geisinger Partner on Prediabetes Study
News

Metabolon, Geisinger Partner on Prediabetes Study

Metabolon, Geisinger Partner on Prediabetes Study
News

Metabolon, Geisinger Partner on Prediabetes Study

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Metabolon, Geisinger Partner on Prediabetes Study"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The study, which will monitor prediabetic subjects using Quantose IR, hemoglobin A1c and fasting plasma glucose (FPG) results over a 12-week period, will be conducted by the Cardiovascular Center for Clinical Research at Geisinger Medical Center in Danville, PA. Study participants will be on a regimen of metformin, diet and exercise.

“As a physician, being able to identify which patients with prediabetes are at greatest risk for developing type 2 diabetes and which are at lowest risk would be extraordinarily helpful,” commented Peter Berger, M.D., chair of cardiology, study investigator and director of the Cardiovascular Center for Clinical Research at Geisinger. “Diabetes affects nearly 900,000 adults in Pennsylvania, which is nine percent of the population. There are three times as many adults with prediabetes; that’s 2.7 million people! Many will progress to full-blown diabetes, so we are eager to explore the use of a new test that may help us identify which patients need the most aggressive therapy to prevent the development of diabetes and which are at lowest risk and need less aggressive therapy.”

Quantose IR is a convenient, cost-effective test that requires only a single fasting blood sample. The test measures the blood concentration levels of specific metabolites that reflect insulin resistance, an early indication of prediabetes.

“We are pleased to work with Dr. Berger’s research team at Geisinger and hope this collaboration is the beginning of an ongoing partnership,” said John Ryals, Ph.D., president and CEO of Metabolon. “This study is important because it has the potential to document the effectiveness of Quantose IR as a monitor for prediabetes therapy. Our goal is to provide physicians with a new tool that can track changes in insulin resistance that may be missed by other glycemic tests such as fasting plasma glucose and hemoglobin A1c.”

The vast majority of people with prediabetes don’t know they have it. A person with prediabetes has a blood sugar level higher than normal, but not high enough for a diagnosis of type 2 diabetes. If left untreated, individuals with prediabetes are at higher risk of progressing to type 2 diabetes, for which there is no cure. Research has shown that many of the complications associated with diabetes are already developing during the prediabetes phase. Diabetes is a leading cause of heart disease, stroke, kidney disease, blindness and amputation.


Advertisement